The role of B-1 cells in cancer progression and anti-tumor immunity.

Autor: Rodríguez-Zhurbenko, Nely, Hernández, Ana M.

Publikováno v: Frontiers in Immunology; 2024, p1-14, 14p

Subvisible Particulate Matter in Therapeutic Protein Injections.

Autor: Novik, E. S.¹ (AUTHOR) Novik@expmed.ru, Dorenskaya, A. V.¹ (AUTHOR), Borisova, N. A.¹ (AUTHOR), Gunar, O. V.¹ (AUTHOR)

Publikováno v: Pharmaceutical Chemistry Journal. Jul2019, Vol. 53 Issue 4, p353-360. 8p.

A High Threshold of Biotherapeutic Aggregate Numbers is Needed to Induce an Immunogenic Response In Vitro, In Vivo, and in the Clinic.

Autor: Cohen JR; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA. jcohen02@amgen.com., Brych SR; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Prabhu S; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Bi V; The Department of Biosimilars, Amgen Inc, Thousand Oaks, CA, 91320, USA., Elbaradei A; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Tokuda JM; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Xiang C; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Hokom M; The Department of Clinical Immunology, Amgen Inc, Thousand Oaks, CA, 91320, USA.; Department of BioAnalytical Sciences, Genentech, Inc, South San Francisco, CA, 94080, USA., Cui X; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Ly C; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Amos N; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Sun J; Translational Safety and Bioanalytical Sciences, Amgen Inc, Thousand Oaks, CA, 91320, USA., Calamba D; Translational Safety and Bioanalytical Sciences, Amgen Inc, Thousand Oaks, CA, 91320, USA., Herskovitz J; The Department of Clinical Immunology, Amgen Inc, Thousand Oaks, CA, 91320, USA.; Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA., Capili A; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Nourbakhsh K; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Merlo A; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Carreon J; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Wypych J; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Narhi LO; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Jawa V; The Department of Clinical Immunology, Amgen Inc, Thousand Oaks, CA, 91320, USA.; Department of Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Princeton, NJ, 08543, USA., Joubert MK; The Department of Process Development, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA. mjoubert@amgen.com.

Publikováno v: Pharmaceutical research [Pharm Res] 2024 Apr; Vol. 41 (4), pp. 651-672. Date of Electronic Publication: 2024 Mar 22.

Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes.

Autor: St. Clair, J. Benjamin^1,2,3, Detanico, Thiago^1,3, Aviszus, Katja^1,3, Kirchenbaum, Greg A.³, Christie, Merry⁴, Carpenter, John F.⁴, Wysocki, Lawrence J.¹ wysockil@njhealth.org

Publikováno v: PLoS ONE. 1/23/2017, Vol. 12 Issue 1, p1-22. 22p.

LN Monocytes Limit DC-Poly I:C Induced Cytotoxic T Cell Response via IL-10 and Induction of Suppressor CD4 T Cells.

Autor: Tewari, Anita, Prabagar, Miglena G., Gibbings, Sophie L., Rawat, Kavita, Jakubzick, Claudia V.

Publikováno v: Frontiers in Immunology; 10/6/2021, Vol. 12, p1-11, 11p